vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and TrueCar, Inc. (TRUE). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $43.2M, roughly 1.7× TrueCar, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -7.2%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $11.2M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 2.3%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
TrueCar, Inc. is an American car retailing website company headquartered in Santa Monica, California. It also maintains a sales office in Austin, Texas.
PBYI vs TRUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $43.2M |
| Net Profit | — | $5.0M |
| Gross Margin | 69.3% | — |
| Operating Margin | 22.7% | -17.0% |
| Net Margin | — | 11.6% |
| Revenue YoY | 27.7% | -7.2% |
| Net Profit YoY | — | 185.7% |
| EPS (diluted) | $0.26 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | — | ||
| Q3 25 | $54.5M | $43.2M | ||
| Q2 25 | $52.4M | $47.0M | ||
| Q1 25 | $46.0M | $44.8M | ||
| Q4 24 | $59.1M | $46.2M | ||
| Q3 24 | $80.5M | $46.5M | ||
| Q2 24 | $47.1M | $41.8M | ||
| Q1 24 | $43.8M | $41.1M |
| Q4 25 | — | — | ||
| Q3 25 | $8.8M | $5.0M | ||
| Q2 25 | $5.9M | $-7.6M | ||
| Q1 25 | $3.0M | $-10.1M | ||
| Q4 24 | — | $-5.8M | ||
| Q3 24 | $20.3M | $-5.8M | ||
| Q2 24 | $-4.5M | $-13.5M | ||
| Q1 24 | $-4.8M | $-5.8M |
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
| Q4 25 | 22.7% | — | ||
| Q3 25 | 17.6% | -17.0% | ||
| Q2 25 | 12.7% | -18.3% | ||
| Q1 25 | 8.7% | -25.0% | ||
| Q4 24 | 22.6% | -15.4% | ||
| Q3 24 | 27.4% | -15.9% | ||
| Q2 24 | -4.6% | -36.3% | ||
| Q1 24 | -5.3% | -18.2% |
| Q4 25 | — | — | ||
| Q3 25 | 16.2% | 11.6% | ||
| Q2 25 | 11.2% | -16.2% | ||
| Q1 25 | 6.5% | -22.6% | ||
| Q4 24 | — | -12.7% | ||
| Q3 24 | 25.2% | -12.5% | ||
| Q2 24 | -9.6% | -32.3% | ||
| Q1 24 | -11.0% | -14.2% |
| Q4 25 | $0.26 | — | ||
| Q3 25 | $0.17 | — | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $103.2M |
| Total DebtLower is stronger | $22.7M | — |
| Stockholders' EquityBook value | $130.3M | $114.2M |
| Total Assets | $216.3M | $148.7M |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | $103.2M | ||
| Q2 25 | $96.0M | $92.5M | ||
| Q1 25 | $93.2M | $98.0M | ||
| Q4 24 | $101.0M | $111.8M | ||
| Q3 24 | $96.7M | $114.5M | ||
| Q2 24 | $96.8M | $128.0M | ||
| Q1 24 | $107.2M | $133.7M |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
| Q4 25 | $130.3M | — | ||
| Q3 25 | $115.3M | $114.2M | ||
| Q2 25 | $104.7M | $106.4M | ||
| Q1 25 | $97.1M | $111.1M | ||
| Q4 24 | $92.1M | $118.1M | ||
| Q3 24 | $71.1M | $128.0M | ||
| Q2 24 | $48.5M | $143.9M | ||
| Q1 24 | $51.0M | $156.0M |
| Q4 25 | $216.3M | — | ||
| Q3 25 | $202.9M | $148.7M | ||
| Q2 25 | $194.9M | $139.8M | ||
| Q1 25 | $196.2M | $145.0M | ||
| Q4 24 | $213.3M | $159.7M | ||
| Q3 24 | $220.7M | $167.5M | ||
| Q2 24 | $205.0M | $183.0M | ||
| Q1 24 | $214.1M | $193.5M |
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $12.7M |
| Free Cash FlowOCF − Capex | $14.4M | $11.2M |
| FCF MarginFCF / Revenue | 19.1% | 25.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.5% |
| Cash ConversionOCF / Net Profit | — | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | $-19.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $12.7M | ||
| Q2 25 | $14.1M | $-2.8M | ||
| Q1 25 | $3.6M | $-7.9M | ||
| Q4 24 | $15.6M | $5.9M | ||
| Q3 24 | $11.0M | $1.8M | ||
| Q2 24 | $1.0M | $-2.0M | ||
| Q1 24 | $11.2M | $2.0M |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $11.2M | ||
| Q2 25 | $14.1M | $-4.8M | ||
| Q1 25 | $3.6M | $-10.6M | ||
| Q4 24 | $15.6M | $4.1M | ||
| Q3 24 | $11.0M | $-170.0K | ||
| Q2 24 | $1.0M | $-3.6M | ||
| Q1 24 | — | $-511.0K |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | 25.9% | ||
| Q2 25 | 26.8% | -10.2% | ||
| Q1 25 | 7.7% | -23.6% | ||
| Q4 24 | 26.4% | 9.0% | ||
| Q3 24 | 13.7% | -0.4% | ||
| Q2 24 | 2.1% | -8.7% | ||
| Q1 24 | — | -1.2% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 3.5% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.1% | 6.0% | ||
| Q4 24 | 0.0% | 3.7% | ||
| Q3 24 | 0.0% | 4.2% | ||
| Q2 24 | 0.0% | 3.9% | ||
| Q1 24 | 0.0% | 6.2% |
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | 2.55× | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
